Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Operating Leases (2019 - 2026)

Cumberland Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $4.9 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 6.73% to $4.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 million, a 6.73% decrease, with the full-year FY2025 number at $4.9 million, down 6.73% from a year prior.
  • Operating Leases hit $4.9 million in Q4 2025 for Cumberland Pharmaceuticals, down from $5.0 million in the prior quarter.
  • Over the last five years, Operating Leases for CPIX hit a ceiling of $5.6 million in Q4 2023 and a floor of $90016.0 in Q4 2021.
  • Historically, Operating Leases has averaged $3.6 million across 5 years, with a median of $4.8 million in 2025.
  • Biggest five-year swings in Operating Leases: tumbled 95.66% in 2021 and later soared 4994.98% in 2022.
  • Tracing CPIX's Operating Leases over 5 years: stood at $90016.0 in 2021, then soared by 4994.98% to $4.6 million in 2022, then increased by 23.07% to $5.6 million in 2023, then dropped by 6.17% to $5.3 million in 2024, then decreased by 6.73% to $4.9 million in 2025.
  • Business Quant data shows Operating Leases for CPIX at $4.9 million in Q4 2025, $5.0 million in Q3 2025, and $4.7 million in Q2 2025.